BioViva’s journey in gene therapy began with its use of an adeno-associated virus (AAV) vector. The company’s lead gene therapy, BV-702, is AAV-based and is in preclinical development for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback